Skip to content

Benjamin Kelmendi

Yale University, National Center for PTSD

28 papers in the library · 1,131 citations · publishing 2016-2026

Papers

Sort Most recent Most cited

Psychotherapy-supported MDMA treatment for PTSD

Cell Reports Medicine August 1, 2021 John H. Krystal, Benjamin Kelmendi, Ismene L. Petrakis 13 citations

A promising new Phase III study of MDMA plus psychotherapy for PTSD treatment by Mitchell and colleagues that appeared in Nature Medicine raises important new questions about the biology and optimal treatment of this disorder. A promising new Phase III study of MDMA plus psychotherapy for PTSD treatment by Mitchell and colleagues that appeared in Nature Medicine raises important new questions...

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.

Progress in Brain Research 2018 Joseph P Barsuglia, Martin Polanco, Robert Palmer et al. 37 citations

Ibogaine is a plant-derived alkaloid and dissociative psychedelic that demonstrates anti-addictive properties with several substances of abuse, including alcohol. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring psychedelic known to occasion potent mystical-type experiences and also demonstrates anti-addictive properties. The potential therapeutic effects of both compounds...

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS

Depression and Anxiety April 6, 2016 Chadi G. Abdallah, Thomas G. Adams, Benjamin Kelmendi et al. 204 citations

Major depressive disorder (MDD) is a common and debilitating psychiatric disorder. Traditional antidepressants are of limited efficacy and take weeks to months to yield full therapeutic effects. Thus, there is a clear need for effective rapid-acting antidepressant medications. The N-methyl-d-aspartate receptor (NMDA-R) antagonist, ketamine, has received a great deal of attention over the last...